Allon Therapeutics Inc.
NPCUF
$0.0001
$0.000.00%
OTC PK
| 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | 03/31/2012 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.53% | 15.40% | -15.83% | 14.08% | -26.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.46% | -18.34% | -36.82% | 2.02% | -4.60% |
| Operating Income | 62.46% | 18.34% | 36.82% | -2.02% | 4.60% |
| Income Before Tax | 61.70% | -86.44% | 39.02% | -6.43% | 8.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.70% | -86.44% | 39.02% | -6.43% | 8.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.70% | -86.44% | 39.02% | -6.43% | 8.04% |
| EBIT | 62.46% | 18.34% | 36.82% | -2.02% | 4.60% |
| EBITDA | 60.67% | 18.50% | 38.40% | -2.37% | 4.70% |
| EPS Basic | 72.83% | -24.69% | 65.89% | 27.60% | 28.13% |
| Normalized Basic EPS | 72.67% | 45.06% | 65.70% | 30.00% | 28.33% |
| EPS Diluted | 72.83% | -24.69% | 65.89% | 27.60% | 28.13% |
| Normalized Diluted EPS | 72.67% | 45.06% | 65.70% | 30.00% | 28.33% |
| Average Basic Shares Outstanding | 40.32% | 49.73% | 78.40% | 47.06% | 28.06% |
| Average Diluted Shares Outstanding | 40.32% | 49.73% | 78.40% | 47.06% | 28.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |